Nivolumab Sustains 9-Year Survival Benefit in Resected Stage III/IV Melanoma

FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers

A crucial update: The FDA has placed a partial clinical hold on a trial involving Lorigerlimab, a drug being tested for use in gynecologic cancers. Get the full story here.

Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma

Unveiling new strategies on February 25th 2026, this article discusses optimized management of immune-checkpoint inhibitor toxicities in melanoma. Read more here.

FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma

In an announcement made on February 25th 2026, the FDA granted SRN-101 a fast-track designation for the treatment of recurrent high-grade glioma. Full coverage can be found here.

Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma

Researchers have reported early successes in the treatment of multiple myeloma using a novel small molecule. This could mark a promising development in the field.

Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC

An analysis conducted in 2025 compares therapies for oropharyngeal cancer, examining quality of life outcomes. Complete findings can be viewed here.